ANDA 91678, held by Novitium Pharma. Levofloxacin.
As of Nov 16, 2026, ANDA 91678 (Levofloxacin), held by Novitium Pharma, was first approved by FDA on Jun 20, 2011, with 7 approved supplements and 0 published complete response letters.
Levofloxacin oral solution is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria (1, 12.4). Pneumonia: Nosocomial and Community Acquired (1.2, 1.3) Skin and Skin Structure Infections: Complicated and Uncomplicated Chronic bacterial prostatitis Inhalational Anthrax, Post-Exposure Plague Urinary Tract Infections: Complicated (1.9, 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 20, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levofloxacin250MG/10ML · solution;oral | Levofloxacin | Rx |
| Sep 20, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| May 23, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 22, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 18, 2018 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 11, 2015 | Supplement 3Manufacturing | Approved | None posted |
| Mar 8, 2013 | Supplement 2Labeling | Approved | None posted |
| Dec 5, 2011 | Supplement 1Labeling | Approved | None posted |
| Jun 20, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters